387 related articles for article (PubMed ID: 30600905)
1. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.
Cortellini A; Verna L; Porzio G; Bozzetti F; Palumbo P; Masciocchi C; Cannita K; Parisi A; Brocco D; Tinari N; Ficorella C
Thorac Cancer; 2019 Feb; 10(2):347-351. PubMed ID: 30600905
[TBL] [Abstract][Full Text] [Related]
2. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
[TBL] [Abstract][Full Text] [Related]
3. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.
Cortellini A; Palumbo P; Porzio G; Verna L; Giordano AV; Masciocchi C; Parisi A; Cannita K; Ficorella C; Bozzetti F
Thorac Cancer; 2018 Dec; 9(12):1623-1630. PubMed ID: 30259689
[TBL] [Abstract][Full Text] [Related]
4. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
5. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Baldini E; Lunghi A; Cortesi E; Turci D; Signorelli D; Stati V; Melotti B; Ricciuti B; Frassoldati A; Romano G; Ceresoli GL; Illiano A; Verderame F; Fasola G; Ricevuto E; Marchetti P; Pinto C; Cartenì G; Scotti V; Tibaldi C; Fioretto L; Giannarelli D
Lung Cancer; 2020 Feb; 140():59-64. PubMed ID: 31881412
[TBL] [Abstract][Full Text] [Related]
7. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
Takada K; Yoneshima Y; Tanaka K; Okamoto I; Shimokawa M; Wakasu S; Takamori S; Toyokawa G; Oba T; Osoegawa A; Tagawa T; Oda Y; Nakanishi Y; Mori M
J Cancer Res Clin Oncol; 2020 May; 146(5):1217-1225. PubMed ID: 32025867
[TBL] [Abstract][Full Text] [Related]
9. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
[TBL] [Abstract][Full Text] [Related]
10. Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival.
Kiss N; Beraldo J; Everitt S
Support Care Cancer; 2019 Jul; 27(7):2657-2664. PubMed ID: 30478673
[TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer.
Tsukagoshi M; Yokobori T; Yajima T; Maeno T; Shimizu K; Mogi A; Araki K; Harimoto N; Shirabe K; Kaira K
Medicine (Baltimore); 2020 Feb; 99(7):e19059. PubMed ID: 32049805
[TBL] [Abstract][Full Text] [Related]
12. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
13. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
Shiroyama T; Nagatomo I; Koyama S; Hirata H; Nishida S; Miyake K; Fukushima K; Shirai Y; Mitsui Y; Takata S; Masuhiro K; Yaga M; Iwahori K; Takeda Y; Kida H; Kumanogoh A
Sci Rep; 2019 Feb; 9(1):2447. PubMed ID: 30792455
[TBL] [Abstract][Full Text] [Related]
14. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
[TBL] [Abstract][Full Text] [Related]
15. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
[TBL] [Abstract][Full Text] [Related]
16. Impact of pre-treatment C-reactive protein level and skeletal muscle mass on outcomes after stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis of the Japan Clinical Oncology Group study JCOG0403.
Matsuo Y; Nagata Y; Wakabayashi M; Ishikura S; Onishi H; Kokubo M; Karasawa K; Shioyama Y; Onimaru R; Hiraoka M
J Radiat Res; 2021 Sep; 62(5):901-909. PubMed ID: 34350956
[TBL] [Abstract][Full Text] [Related]
17. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
[TBL] [Abstract][Full Text] [Related]
18. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Garassino MC; Crinò L; Catino A; Ardizzoni A; Cortesi E; Cappuzzo F; Bordi P; Calabrò L; Barbieri F; Santo A; Altavilla G; Ambrosio F; Mini E; Vasile E; Morgillo F; Scoppola A; Bengala C; Follador A; Tedde N; Giannarelli D; Lo Russo G; Vitiello F
Tumour Biol; 2018 Nov; 40(11):1010428318815047. PubMed ID: 30486741
[TBL] [Abstract][Full Text] [Related]
20. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
[No Abstract] [Full Text] [Related]
[Next] [New Search]